Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
Checked against the public recordLast updated Apr 1, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- NGM Biopharmaceuticals, Inc
- Interventions being studied
- Drug: NGM438; Drug: Pembrolizumab (KEYTRUDA ®)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy. * Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type for which the patient was eligible and willing to receive. * Adequate bone marrow, kidney and liver function * Performance status of 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement. Exclusion Criteria: • Prior treatment targeting LAIR1
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- SCRI DenverDenver, Colorado
- Yale Cancer CenterNew Haven, Connecticut
- Henry Ford Health SystemDetroit, Michigan
- START MidwestGrand Rapids, Michigan
- Mount Sinai HospitalNew York, New York
- MD AndersonHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 1, 2024. Always confirm current availability with the study team.